Sean G. Kraus

Sean G. Kraus

Auto-generated profile, based on publicly available information

Sean G. Kraus

University of Wisconsin 1 Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
RDRebecca A. DeStefanis
Rebecca A. DeStefanis
ASAlexa E. Schmitz
Alexa E. Schmitz
A(Alyssa Steimle (DeZeeuw)
Alyssa Steimle (DeZeeuw)
SPSusan N. Payne
Susan N. Payne
GSGioia C. Sha
Gioia C. Sha
DDDustin Deming
Dustin Deming
Targeting PIK3CA-mutant colorectal cancers with precision medicine strategies is of great clinical interest. However, resistance to single-agent PI3K pathway inhibitors has been observed across multiple clinical trials, necessitating the identification of combination therapies that overcome or prevent resistance to precision medicine strategies. Previously, our group identified that inhibition of mTORC1/2 is necessary to induce a response in PIK3CA-mutant colorectal cancers. The PI3K/mTORC1/2 inhibitor copanlisib has demonstrated some clinical activity in PIK3CA-mutant solid tumors as part of the NCI-MATCH trial. In this study, we evaluate potential combination therapies that could enhance the efficacy of copanlisib and other similar inhibitors in PIK3CA-mutant colorectal cancers. Using a novel high-throughput drug screen method in Apc- and Pik3ca-mutant mouse-derived cancer organoids, we identify navitoclax, a BCL-2 family inhibitor, as a drug that could potentially enhance the response to copanlisib. Across multiple in vitro and in vivo colorectal cancer models, navitoclax enhanced PI3K/mTOR inhibition (copanlisib, sapanisertib, and dactolisib) and induced apoptosis. Furthermore, we examine these combination therapies across a panel of patient-derived cancer organoids with a range of mutation profiles. These studies indicate that KRAS mutations could confer resistance. Furthermore, we identify BCL-xL as the major BCL-2 family target important for the response to this combination in this setting. This provides a strong rationale for mTORC1/2 and BCL-2 family inhibition as a potential treatment strategy for PIK3CA-mutant colorectal cancers.

24 March 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
DDDustin Deming
Dustin Deming
SKSean G. Kraus
Sean G. Kraus
JBJoshua Brand
Joshua Brand
KJKatherine Johnson
Katherine Johnson
DADaniel Abbott
Daniel Abbott
MBMichael F. Bassetti
Michael F. Bassetti
Purpose: Versican (VCAN) is an immunoregulatory matrix proteoglycan that, when cleaved, releases an immunostimulatory fragment, versikine. In this study, we evaluate the impact of VCAN on immune surveillance and immunotherapy response in a prospective clinical trial. Patients and Methods: T-cell function was assayed in the setting of VCAN. Normal and matched tissues were acquired from 243 patients across colorectal cancer stages. A phase Ib clinical trial enrolled 15 subjects with microsatellite stable oligometastatic colorectal cancer and examined the safety and efficacy of the sequential combination of stereotactic body radiotherapy, pembrolizumab, and resection (NCT02837263). The outcomes were correlated with the VCAN status and circulating immune phenotype by single-cell RNA sequencing. Results: VCAN significantly accumulates in 59% of colorectal cancers and is heavily proteolyzed [VCAN proteolytic predominant (VPP)] in 27% (40% of oligometastatic colorectal cancers). VCAN decreased CD8+ T-cell trafficking (P < 0.01) and activated CD8+ T-cell effector function [decreased IL2RA (P < 0.05), PD-1 (P < 0.05), and granzyme B (GZMB; P < 0.001)]. The clinical trial met the primary endpoint with a 1-year recurrence-free survival (RFS) of 60%. Of those enrolled, 40% had the VPP phenotype, which was associated with a trend toward improved RFS (P = 0.053), and all are still alive with a median follow-up of 4.1 years. The VPP phenotype was associated with enhanced circulating CD8+ T-cell effector function at baseline, which was further enhanced with study treatment. Conclusions: VCAN limits T-cell trafficking and effector function, and its proteolysis correlates with an effector phenotype of circulating CD8+ T cells, greater tumor-infiltrating lymphocytes, and improved clinical outcomes with this immunotherapy-based clinical trial treatment.


2 December 2025
Verified
Other
Open access
RDRebecca A. DeStefanis
Rebecca A. DeStefanis
ASAlexa E. Schmitz
Alexa E. Schmitz
A(Alyssa Steimle (DeZeeuw)
Alyssa Steimle (DeZeeuw)
SPSusan N. Payne
Susan N. Payne
GSGioia C. Sha
Gioia C. Sha
DDDustin Deming
Dustin Deming
Supplementary Data of Sequencing Results from PDCOs.

2 December 2025
Verified
Other
Open access
RDRebecca A. DeStefanis
Rebecca A. DeStefanis
ASAlexa E. Schmitz
Alexa E. Schmitz
A(Alyssa Steimle (DeZeeuw)
Alyssa Steimle (DeZeeuw)
SPSusan N. Payne
Susan N. Payne
GSGioia C. Sha
Gioia C. Sha
DDDustin Deming
Dustin Deming
Supplementary Figure 3. Combination of copanlisib and navitoclax enhances apoptosis in multiple models of CRC.

2 December 2025
Verified
Other
Open access
RDRebecca A. DeStefanis
Rebecca A. DeStefanis
ASAlexa E. Schmitz
Alexa E. Schmitz
A(Alyssa Steimle (DeZeeuw)
Alyssa Steimle (DeZeeuw)
SPSusan N. Payne
Susan N. Payne
GSGioia C. Sha
Gioia C. Sha
DDDustin Deming
Dustin Deming
Supplementary Figure 4. Combination of copanlisib and navitoclax does not significantly alter the RAS/RAF pathway.